Format

Send to

Choose Destination
See comment in PubMed Commons below
Ann Oncol. 2013 Sep;24(9):2342-9. doi: 10.1093/annonc/mdt231. Epub 2013 Jul 12.

Bevacizumab plus chemotherapy continued beyond first progression in patients with metastatic colorectal cancer previously treated with bevacizumab plus chemotherapy: ML18147 study KRAS subgroup findings.

Collaborators (237)

Andel J, Balcke P, Benedicic B, Eisterer W, Fridrik M, Jagdt B, Keil F, Kretschmer A, Krippl P, Oexle H, Pecherstorfer M, Samonigg H, Schmid M, Thaler J, Tinchon C, Weiss H, Arts J, De Man M, Demolin G, Janssens J, Polus M, Benczikova B, Melichar B, Prausova J, Vitek P, Andersen F, Jensen B, Keldsen N, Osterlind K, Vistisen K, Elme A, Magi A, Ojamaa K, Ristamäki R, Salminen T, Ben Abdelghani M, Bouche O, Borg C, Bouhier-Leporrier K, Breysacher G, Chone L, Clavero Fabri MC, Deplanque G, Desseigne F, Dourthe LM, Ezenfis J, Faroux R, François E, Garnier C, Gaspard MH, Hebbar M, Illory J, Kaminsky MC, Lecomte T, Legoux JL, Levache B, Lobry C, Lotz JP, Mabro M, Manet-Lacombe S, Manfredi S, Matysiak Budnik T, Miglianico L, Mineur L, Moullet I, Naman H, Nouyrigat P, Oziel-Taieb S, Perrier H, Pezet D, Philip J, Pottier V, Porneuf M, Ramdani M, Re D, Rinaldi Y, Spaeth D, Taieb J, Terrebonne E, Texereau P, Thirot Bidault A, Tournigand C, Tubiana-Mathieu N, Vantelon JM, Viret F, Ychou M, Bangerter M, Bertram M, Bohnsteen B, Brinkmann L, Caca K, Constantin C, Cordes HJ, Dietrich G, Eggert J, Engel E, Fahlke J, Fensterer H, Florschütz A, Folprecht G, Forstbauer H, Freier W, Freund M, Frickhofen N, Gäbele E, Geißler M, Gieseler F, Göhler T, Graeven U, Groschek M, Grundeis M, Hacker U, Hagen V, Hebart H, Hegewisch-Becker S, Heike M, Herrmann T, Hildebrandt B, Höffkes HG, Hübner G, Hübner J, Kettner E, Kneba M, Kohnke J, Kojouharoff G, König C, Kretzschmar A, Kröning H, Kürner K, Lammert F, Lerchenmüller C, Lück A, Meiler J, Mergenthaler HG, Müller L, Müller-Naendrup C, Nusch A, Papke J, Porschen R, Rädle J, Reddemann C, Ridwelski K, Riera-Knorrenschild J, Rudi J, Schmalenberger A, Schimanski CC, Schlegel F, Schlichting C, Schmidt P, Schmiegel W, Schmitz S, Schulze-Bergkamen H, Schwaner I, Schwarzer A, Schwerdtfeger M, Selbach J, Sieber M, Siebler J, Staib P, Stauch M, Steffens CC, Stübs P, Tischendorf J, Trarbach T, Tummes D, Valdix AR, Vogel A, Von Wichert G, Walther M, Welslau W, Wilhelm G, Wobster H, Wolf T, Zeigenhagen N, Zomorodbaksch B, Batman E, Bloemendal H, Kehrer D, Guren T, Indrebø G, Kersten C, Soerbye H, Fragoso M, Fragoso R, Mellidez J, Sa A, Aljobran A, Darwish T, Alonso-Orduna V, Aparicio J, Aranda E, Bosch C, Galan-Brotons A, Busquier Hernandez I, Camara J, Campos Cervera J, Carlos Garcia Giron C, Del Prado P, Donnay O, Escudero P, Falco E, Gallego Plazas J, Garcia Alfonso P, Gonzalez Flores E, Gravalos C, Guardeno R, Juárez A, Lopez Ladron A, Losa Gaspa F, M Vicent Vergé J, Marcuello Gaspar E, Massuti Sureda B, Molina J, Montero I, Muñoa A, Naranjo M, Oruezabal Moreno M, Pachón Olmos V, Pericay C, Reina Zoilo J, Rivera F, Ruiz Casado A, Safont M, Salud Salvia A, Tobena M, Toral J, Valenti V, Valladares Ayerbes M, Vieitez J, Vera R, Vieitez J, Berglund A, Fernebro E, Hess-Umbricht V, Pless M, Popescu R, Winterhalder R.

Author information

1
Cancer Center Reutlingen, Reutlingen, Germany. kubicka_s@klin-rt.de

Abstract

BACKGROUND:

ML18147 evaluated continued bevacizumab with second-line chemotherapy for patients with metastatic colorectal cancer (mCRC) progressing after the standard first-line bevacizumab-containing therapy.

PATIENTS AND METHODS:

Evaluating outcomes according to tumor Kirsten rat sarcoma virus oncogene (KRAS) status was an exploratory analysis. KRAS data were collected from local laboratories (using their established methods) and/or from a central laboratory (mutation-specific Scorpion amplification-refractory mutation system). No adjustment was made for multiplicity; analyses were not powered to detect statistically significant differences.

RESULTS:

Of 820 patients, 616 (75%) had unambiguous KRAS data; 316 (51%) had KRAS wild-type tumors and 300 (49%) had mutant KRAS tumors. The median progression-free survival (PFS) was 6.4 months for bevacizumab plus chemotherapy and 4.5 months for chemotherapy [P < 0.0001; HR = 0.61; 95% confidence interval (CI): 0.49-0.77] for wild-type KRAS and 5.5 and 4.1 months, respectively (P = 0.0027; HR = 0.70; 95% CI: 0.56-0.89) for mutant KRAS. The median overall survival (OS) was 15.4 and 11.1 months, respectively (P = 0.0052; HR = 0.69; 95% CI: 0.53-0.90) for wild-type KRAS and 10.4 versus 10.0 months, respectively (P = 0.4969; HR = 0.92; 95% CI: 0.71-1.18) for mutant KRAS. In both analyses, no treatment interaction by KRAS status was observed (PFS, P = 0.4436; OS, P = 0.1266).

CONCLUSIONS:

Bevacizumab beyond first progression represents an option for patients with mCRC treated with bevacizumab plus standard first-line chemotherapy, independent of KRAS status.

TRIAL REGISTRATION:

ClinicalTrials.gov NCT00700102.

KEYWORDS:

KRAS mutation status; bevacizumab; chemotherapy; colorectal cancer

PMID:
23852309
DOI:
10.1093/annonc/mdt231
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments

    Supplemental Content

    Full text links

    Icon for Silverchair Information Systems
    Loading ...
    Support Center